NPC1 and hyperinsulinemic hypoglycemia, familial, 4: Our findings help define dose ranges, treatment ages, and efficacy in hypomorphic models of NPC1 deficiency and suggest that higher doses of AAV9-h<i>NPC1</i> in presymptomatic disease states are likely to yield better outcomes in NPC1 individuals.